PPARG and prostate cancer: Although genetic deficiency of PPARγ does not alter the development of experimental prostate cancer [30], individual PPARγ ligands have been shown to inhibit in vitro cellular proliferation of both human bladder and prostate carcinoma cell lines [1,2,31-34].